Dr. Zuoxiang Xiao is the Founder, Chairman, and Chief Executive Officer of CentryMed. He holds a Ph.D. in Oncology from Zhejiang University and is a Senior Engineer in Biopharmaceutical Sciences. With over 30 years of experience in oncology, immunopathology, and innovative antibody drug development, Dr. Xiao has held research positions at leading institutions including the Johns Hopkins Bloomberg School of Public Health, Johns Hopkins School of Medicine, and the U.S. National Cancer Institute (NCI).

Dr. Xiao is internationally recognized for his groundbreaking contributions in tumor biology and therapeutic discovery. He was the first in the world to establish a murine model for non-small cell squamous carcinoma, and discovered the use of zinc chelators to inhibit HIV replication, offering a novel pathway for antiviral drug development. He has authored more than 30 peer-reviewed publications in high-impact journals such as Cancer Cell, Genes & Development, and PNAS, with over 3,000 citations.

As a visionary scientist and entrepreneur, Dr. Xiao has led the development of multiple next-generation antibody platforms and continues to drive CentryMed's mission to create transformative medicines for patients worldwide.

Dr. Dongwen Zhou is Vice President of R&D at CentryMed. He received his Ph.D. in Biology from the University of Science and Technology of China and completed postdoctoral training at the U.S. National Cancer Institute. He also served as a research scientist at the Blood Research Institute of the University of Wisconsin.

Dr. Zhou specializes in the structural and functional analysis of disease-associated proteins, with nearly 20 years of research experience in biologics for cancer and autoimmune diseases. His research includes the first elucidation of the extended subunit conformation of integrin αIIbβ3, a key protein in platelet activation, and the first high-resolution structure of PECAM-1, revealing critical insights into its conformational changes during vascular signaling. He has published more than 20 scientific papers in journals such as Blood and PNAS, and is the recipient of the ACA Young Scientist Award, NIH Postdoctoral Fellowship, and the Medical College of Wisconsin Postdoctoral Researcher Award.

Co-founder of CICCB Investment (CICC & CCBtrust MedTech Investment JV Platform). Advisor of Sino-Singapore Tianjin Eco-City Biomedical Industrial Park and advisor of Shanghai Biomedical Investment & Financing Association.

Over a decade of extensive experience in international healthcare industry and capital markets. Qualifications in US healthcare management, and Chinese securities, futures, fund management, investment advisory, as well as securities and futures trading licenses.

Ms. Yanping Wang serves as the COO of CentryMed's U.S. subsidiary-CentryMed US. She holds a master degree from Peking Union Medical College and previously served as a researcher at the U.S. National Cancer Institute. She oversees the operational strategy and execution for CentryMed US's activities, including early antibody library construction and therapeutic candidate development.

With nearly two decades of hands-on experience in antibody drug development, Ms. Wang brings deep expertise in monoclonal cell line generation, antibody expression, purification, and endotoxin removal. During her tenure at NIH, she led the expression and large-scale production of various humanized monoclonal antibodies—including scFv, Fab, and full-length IgGs—in both eukaryotic and prokaryotic systems, tailoring purification approaches to antibody-specific characteristics. She is also an inventor on multiple U.S. patent filings.

Mr. Jiangnan Zhang is Director of Clinical Medical Science at CentryMed. He holds a master's degree in Medical Oncology from Shandong University School of Medicine and has extensive clinical experience in oncology treatment and drug development.

Mr. Zhang has led multiple IND submissions for innovative oncology drugs, both in China and internationally. He specializes in clinical strategy formulation, early- and late-phase trial design and execution, medical data analysis, and regulatory-compliant medical writing. Dedicated to integrating clinical experience with drug development to advance the research of innovative pharmaceuticals.